Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. faced a notable stock decline, reflecting ongoing financial challenges. The company has experienced a steep drop over the past month and year-to-date, significantly underperforming compared to the broader market. Key financial metrics indicate low management efficiency and a high debt-to-equity ratio.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. faced a notable stock decline, contrasting with the modest gain of the China Shanghai Composite. The company has experienced significant drops in its stock over various time frames, alongside concerning financial metrics, including low ROCE and negative ROE, raising questions about its stability and growth.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. faced notable stock volatility on June 1, 2026, with a significant decline. Over the past week and month, the stock has shown considerable drops, reflecting ongoing financial challenges, including low profitability and a high debt-to-equity ratio, despite its substantial market capitalization.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. faced a significant stock decline today, reaching an intraday low amid a challenging trading environment. The company's financial metrics reveal low profitability and high debt levels, contributing to concerns about its long-term growth potential, despite a modest weekly increase.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a notable stock price increase on May 21, 2026, despite a broader market decline. The company has shown positive weekly and monthly trends, but its one-year performance lags behind the market. Challenges include low profitability metrics and high debt levels.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. has seen a notable rise in its stock today, contrasting with the modest gains of the China Shanghai Composite. Over the past week and month, Dizal has outperformed the broader market, though it faces challenges related to profitability and long-term growth.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a notable increase in stock performance today, contrasting with the broader market trends. Despite recent gains and a strong weekly performance, the company faces challenges such as low Return on Capital Employed and a high Debt to Equity ratio, indicating potential long-term financial hurdles.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Over the past week and month, the stock has faced notable decreases. Despite a modest annual gain, the company struggles with high debt levels and negative returns on equity, indicating ongoing challenges.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. faced a significant stock decline, contrasting with the minor decrease in the China Shanghai Composite. Despite a slight weekly increase, Dizal's longer-term performance shows an 8.97% drop over the past month and concerns over profitability and financial stability persist.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. faced a significant stock decline amid a challenging market, reaching an intraday low. Despite a weekly gain, its one-month performance remains negative. Concerns about financial health are highlighted by low profitability metrics and a high debt-to-equity ratio, indicating potential long-term growth issues.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a significant intraday increase on March 10, 2026, outperforming the China Shanghai Composite. However, its longer-term performance reveals challenges, with declines over the past month and year-to-date. Key financial metrics indicate concerns regarding the company's financial health.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a significant intraday gain today, contrasting with the modest rise of the China Shanghai Composite. However, its longer-term performance reveals declines over the past week, month, and year-to-date, alongside concerning financial indicators and a high debt-to-equity ratio.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Over the past week, the company has faced a notable downturn, with year-to-date and one-year returns lagging behind the market. Financial metrics indicate challenges in management efficiency and stability.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a notable stock decline today, contrasting with the broader market's performance. Over the past month, the company has faced significant challenges, including a decrease in stock value and concerns regarding management efficiency and high debt levels, raising questions about its growth potential.